Funding for this research was provided by:
Cancer research UK (A13244 and C16708)
Kay Kendall Leukaemia Fund (KKL1071)
Yorkshire Cancer Research (L374RA)
Received: 13 February 2019
Accepted: 6 June 2019
First Online: 1 July 2019
Ethics approval and consent to participate
: All blood samples were obtained from patients diagnosed with AML or patients taking part in the STORM Phase 1 clinical trial (NCT02043665/Keynote-200/VLA009A) following additional informed consent. Written, informed consent was obtained from all patients in accordance with local institutional ethics review and approval (Leeds Teaching Hospital NHS Trust; 06/Q1206/106).
: Not applicable.
: D.S is affiliated with Viralytics Ltd. No other author has any competing interests to declare.